683 Capital Management’s Connect Biopharma Holdings CNTB Stock Holding History

683 Capital Management’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.36M	Buy	+900,000	New	+$2.35M	0.12%	99

Other funds holding CNTB

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Susquehanna International Group

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

683 Capital Management's CNTB Position: Q1 2026 in Review

683 Capital Management opened a new position in Connect Biopharma Holdings (CNTB) in Q1 2026: 900,000 shares worth $2.36M. The stake represents 0.12% of the portfolio and ranks #99 among its holdings.

41 funds tracked by Wall St. Rank hold CNTB as of Q1 2026.

683 Capital Management held 900,000 shares of Connect Biopharma Holdings worth $2.36M as of Q1 2026.
Connect Biopharma Holdings was a new 683 Capital Management position in Q1 2026.
Connect Biopharma Holdings made up 0.12% of 683 Capital Management's portfolio in Q1 2026, its #99 holding.
41 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.